Candidates identified from the initial screen ( miR-323-3p , miR-652 , miR-27b , miR-103 and miR-208a ) were validated in a further cohort of 200 patients at baseline ( ~ 30 days post-ACS ) and at 4 and 12 months post-ACS , and compared with 100 controls .